Can-Fite BioPharma Ltd.

CANF

IL0010944739

Pharmaceuticals

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:21 2025-07-10 am EDT			5-day change	1st Jan Change
1.300 ^ILa	+8.33%		+8.33%	-31.58%

Jun. 16	Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston	CI
May. 05	Can-Fite Says It Has Raised $175 Million To Date For Development Of Namodenoson And Piclidenoson	RE

Can-Fite Says It Has Raised $175 Million To Date For Development Of Namodenoson And Piclidenoson

Published on 05/05/2025 at 08:40

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Can-Fite BioPharma Ltd.

Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston	Jun. 16	CI
Can-Fite Says It Has Raised $175 Million To Date For Development Of Namodenoson And Piclidenoson	May. 05	RE
Can-Fite Biopharma Ltd. Announces FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson	Apr. 17	CI
Can-Fite Announces $3.0 Million Registered Direct Offering Of American Depositary Shares	Apr. 14	RE
Can-Fite BioPharma Projects $685 Million in Future Revenue via Collaborations	Apr. 14	MT
Can-Fite Reports 2024 Financial Results And Clinical Update	Apr. 14	RE
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	Apr. 14	CI
Can-Fite BioPharma Begins Late-Stage Study of Prospective Psoriasis Medication	Mar. 24	MT
Can-Fite BioPharma Ltd. Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol	Mar. 24	CI
Can-Fite BioPharma Ltd. Announces to Initiate Phase II Study in Rare Genetic Disease Lowe Syndrome with Piclidenoson	Mar. 19	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 18	MT
Sector Update: Health Care Stocks Edge Down in Afternoon Trading	Mar. 18	MT
Sector Update: Health Care	Mar. 18	MT
Can-Fite Says US FDA Approves Compassionate Use Treatment With Namodenoson in Pancreatic Cancer Patient	Mar. 18	MT
Can-Fite BioPharma Ltd. Receives Single FDA Approval for the Compassionate Use Treatment of U.S. Based Pancreatic Cancer Patient with its Anti-Cancer Drug Namodenoson	Mar. 18	CI
Can-Fite BioPharma Ltd. - Special Call	Feb. 25
Can-Fite BioPharma Ltd. Announces US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug	Jan. 27	CI
Recognition of the American Society of Clinical Oncology of the Liver Protective Effect of Can-Fite?s anti-Cancer Drug Namodenoson	Dec. 30	CI
Can-Fite Biopharma Ltd. Announces 8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite?s Namodenoson Drug	Dec. 04	CI
Can-Fite BioPharma Ltd. - Special Call	Nov. 23
Can-Fite BioPharma Doses First Patient in Namodenoson Phase 2a Trial in Pancreatic Cancer	Nov. 11	MT
Can-Fite BioPharma Ltd. Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial	Nov. 11	CI
Can-Fite BioPharma Ltd. - Special Call	24-10-29
Can-Fite BioPharma's Partner Reports Positive Study Results of Piclidenoson in Dogs With Osteoarthritis	24-10-18	MT
Can-Fite BioPharma Ltd.'s Partner Vetbiolix Reports Positive Results in Dog Osteoarthritis Study with Piclidenoson	24-10-18	CI

Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Employees

Sector

Pharmaceuticals

Calendar

Aug. 27 - Q2 2025 Earnings Release (Projected)

More about the company